Anchorage launches Agentic Banking to provide compliant fund access for AI
According to Odaily, Anchorage Digital co-founder Nathan McCauley announced on the X platform the launch of Agentic Banking, aimed at providing AI systems with compliant and governable access to funds. This includes identity authentication, policy control, and settlement capabilities across both crypto and traditional financial systems, enabling AI to participate directly in economic activities within a regulated framework. This system leverages its US federal chartered crypto bank qualification to offer a compliant "execution layer," ensuring transactions have access control, real-time risk management, and auditability.
Nathan McCauley further pointed out that the financial system is entering the "era of autonomy," with AI shifting from an auxiliary decision-making tool to an entity capable of independently executing tasks, such as performing workflows, engaging in negotiations, and representing institutions in operations. The current financial system is not yet prepared for "non-human participants" and lacks identity systems for AI, policy execution mechanisms, and compliant access to funds, forcing institutions to compromise between automation and risk.
Anchorage previously partnered with Google Cloud, with the latter building the "intelligence layer" to support discovery, collaboration, and decision-making among AI agents, while Anchorage handles fund execution and settlement. This partnership promotes moving institutional digital asset infrastructure to the cloud, integrating custody, key management, trade governance, and staking capabilities, helping financial institutions embed stablecoins and digital assets into their products.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
